Chronic Coronary Artery Disease: Wall Disease vs. Lumenopathy

被引:0
作者
Paraskevaidis, Ioannis [1 ,2 ]
Kourek, Christos [1 ]
Tsougos, Elias [2 ]
机构
[1] Natl & Kapodistrian Univ Athens, Med Sch Athens, Athens 15772, Greece
[2] Hygeia Hosp, Dept Cardiol, Athens 15123, Greece
关键词
chronic coronary artery disease; myocardial ischemia; wall disease; lumenopathy; OPTICAL COHERENCE TOMOGRAPHY; SMOOTH-MUSCLE-CELLS; OF-THE-ART; INTRAVASCULAR ULTRASOUND; ATHEROSCLEROTIC PLAQUE; VASCULAR ENDOTHELIUM; NITRIC-OXIDE; RISK; INFLAMMATION; COLCHICINE;
D O I
10.3390/biom15020201
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acute and chronic coronary artery disease (CAD) are interconnected, representing two facets of the same condition. Chronic CAD exhibits a dynamic nature, manifesting as stable or acute ischemia, or both. Myocardial ischemia can be transient and reversible. The genesis of CAD involves diverse anatomical and functional mechanisms, including endothelial dysfunction, arteriolar remodeling, capillary rarefaction, and perivascular fibrosis, though no single factor explains its heterogeneity. Chronic CAD is often stable but may present as symptomatic or asymptomatic (e.g., in diabetes) and affect various coronary compartments (epicardial or microcirculation). This complexity necessitates a reappraisal of our approach, as pathophysiological mechanisms vary and often overlap. A comprehensive exploration of these mechanisms using advanced diagnostic techniques can aid in identifying the dynamic processes underlying CAD. The disease may present as obstructive or non-obstructive, stable or unstable, underscoring its diversity. The primary source of CAD lies in the arterial wall, emphasizing the need for research on its components, such as the endothelium and vascular smooth muscle cells, and factors disrupting arterial homeostasis. Shifting focus from arterial luminal status to the arterial wall can provide insights into the genesis of atheromatous plaques, enabling earlier interventions to prevent their development and progression.
引用
收藏
页数:20
相关论文
共 126 条
  • [1] Vrints C., Andreotti F., Koskinas K.C., Rossello X., Adamo M., Ainslie J., Banning A.P., Budaj A., Buechel R.R., Chiariello G.A., Et al., ESC 2024 Guidelines for the management of chronic coronary syndromes, Eur. Heart J, 45, pp. 3415-3537, (2024)
  • [2] Jebari-Benslaiman S., Galicia-Garcia U., Larrea-Sebal A., Olaetxea J.R., Alloza I., Vandenbroeck K., Benito-Vicente A., Martin C., Pathophysiology of Atherosclerosis, Int. J. Mol. Sci, 23, (2022)
  • [3] Scarsini R., Fezzi S., Leone A.M., De Maria G.L., Pighi M., Marcoli M., Tavella D., Pesarini G., Banning A.P., Barbato E., Et al., Functional patterns of coronary disease: Diffuse, focal, and serial lesions, JACC Cardiovasc. Interv, 15, pp. 2174-2191, (2022)
  • [4] Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O'Brien S.M., Boden W.E., Chaitman B.R., Senior R., Lopez-Sendon J., Alexander K.P., Et al., Initial invasive or conservative strategy for stable coronary disease, N. Engl. J. Med, 382, pp. 1395-1407, (2020)
  • [5] Hochman J.S., Anthopolos R., Reynolds H.R., Bangalore S., Xu Y., O'Brien S.M., Mavromichalis S., Chang M., Contreras A., Rosenberg Y., Et al., Survival after invasive or conservative management of stable coronary disease, Circulation, 147, pp. 8-19, (2023)
  • [6] Lopes R.D., Alexander K.P., Stevens S.R., Reynolds H.R., Stone G.W., Pina I.L., Rockhold F.W., Elghamaz A., Lopez-Sendon J.L., Farsky P.S., Et al., Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction, Circulation, 142, pp. 1725-1735, (2020)
  • [7] Fearon W.F., Zimmermann F.M., De Bruyne B., Piroth Z., van Straten A.H.M., Szekely L., Davidavicius G., Kalinauskas G., Mansour S., Kharbanda R., Et al., Fractional flow reserve-guided PCI as compared with coronary bypass surgery, N. Engl. J. Med, 386, pp. 128-137, (2022)
  • [8] Sabatine M.S., Bergmark B.A., Murphy S.A., O'Gara P.T., Smith P.K., Serruys W., Kappetein A.P., Park S.J., Park D.W., Christiansen E.H., Et al., Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: An individual patient data meta-analysis, Lancet, 398, pp. 2247-2257, (2021)
  • [9] Rozanski A., Miller R.J.H., Gransar H., Han D., Slomka P., Dey D., Hayes S.W., Friedman J.D., Thomson L., Berman D.S., Benefit of early revascularization based on inducible ischemia and left ventricular ejection fraction, J. Am. Coll. Cardiol, 80, pp. 202-215, (2022)
  • [10] Reynolds H.R., Shaw L.J., Min J.K., Page C.B., Berman D.S., Chaitman B.R., Picard M.H., Kwong R.Y., O'Brien S.M., Huang S., Et al., Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity, Circulation, 144, pp. 1024-1038, (2021)